Takeda Pharmaceutical Co ADR (NYSE:TAK) does about 2.13M shares in volume on a normal day but saw 1105752 shares change hands in the recent trading day. The company now has a market cap of 47.12B USD. Its current market price is $14.97, marking a decrease of -0.73% compared to the previous close of $15.08. The 52 week high reached by this stock is $15.43 whilst the lowest price level in 52 weeks is $12.57.
The consensus objective for the share price is $17.20, suggesting that the stock has a potential upside of 12.97% over the period.
FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
BofA Securities also upgraded the stock to “Buy” from Neutral on March 16, 2023 at a price target of $20. Cowen upgraded its price target at $21-$24.
The current price level is 3.41%, 1.81%, and 5.48% away from its SMA20, SMA50, and SMA200 respectively, with the TAK price moving above the 50-day SMA on current market day. Takeda Pharmaceutical Co ADR (TAK) stock is up 2.04% over the week and -2.28% over the past month. Its price is 13.07% year-to-date and 14.89% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year. Expected sales for next quarter are $1.15T, which analysts say will come at $4.6T for the current fiscal year and next year at $4.61T. In addition, estimates put the company’s current quarterly revenue at an average of $1.16T.
To reach the target analysts have set, the stock logically needs to grow 12.97 percent from here.
Outstanding shares total 3.15B with insiders holding 0.01% of the shares and institutional holders owning 2.30% of the company’s common stock. The company has a return on investment of 0.97% and return on equity of 1.50%. The price to earnings ratio (P/E ratio) amounts to 68.89 while the forward price to earnings ratio is 22.55. The beta has a value of 0.26. Price to book ratio is 1.02 and price to sales ratio is 1.57.
